



Office of the Secretary

United States of America
FEDERAL TRADE COMMISSION
Washington, DC 20580

October 31, 2017

Phillip A. Proger, Esq.
Aimee E. DeFilippo, Esq.
Jones Day
51 Louisiana Avenue N.W.
Washington, DC 20001-2113
Counsel for Celgene Corporation

Re: *Celgene Corporation, FTC File No. 081-0172*

Dear Mr. Proger and Ms. DeFilippo:

The Federal Trade Commission's Bureau of Competition has conducted a non-public investigation to determine whether Celgene Corporation may have violated Section 2 of the Sherman Act, 15 U.S.C. § 2, or Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, in connection with its production and sale of the prescription drugs Thalomid and Revlimid and the prospective production and sale of generic bioequivalent drugs by competing firms.

Upon further review of this matter, the Commission determined that no further action was warranted, and closed the investigation. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

Donald S. Clark
Secretary